Glaucoma

Top Story

Eye movements may contribute to optic nerve damage in glaucoma

January 12, 2018
Perspectives on Glaucoma

Patients on glaucoma drugs have significant meibomian gland dropout

January 10, 2018
Patients treated with anti-glaucoma medications have significant meibomian gland dropout, and the effect is proportional to the number of medications and instillations…

iDose travoprost shows sustained IOP reduction at 12 months in phase 2 trial

January 10, 2018
A sustained reduction in IOP was seen in a 12-month interim cohort of patients in an investigational new drug phase 2 clinical trial of the travoprost intraocular…

Free glaucoma resources available for National Glaucoma Awareness Month

January 5, 2018
As the number of age-related eye disease cases is projected to grow with the aging U.S. population, January has been declared National Glaucoma Awareness Month in an…
More Headlines »
CME

Medical Management of Glaucoma: Recent Approvals and Drugs Under Investigation

This activity is supported by educational grants from Aerie Pharmaceuticals, Inc.; Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

Glaucoma is the leading cause of irreversible blindness worldwide, with an estimated 70 million people affected by the…
More »
Video
Meeting News

VIDEO: MIGS aids astigmatism management in patients with glaucoma

October 30, 2017
More »
Resource Centers
American Academy of Optometry

American Academy of Optometry

Video
Meeting News

VIDEO: FDA panel gives overwhelming support to Rhopressa approval

November 1, 2017
More »
Advertisement
Advertisement